A University of Pittsburgh spinout company has received $62 million in its latest round of venture funding, which will jumpstart the second phase trials of its first drug candidate.

Complexa Inc., which was founded in 2008 by Bruce Freeman, 65, chair of Pitt’s department of pharmacology and chemical biology, is a clinical stage biopharmaceutical company developing compounds that address inflammatory reactions in humans implicated in a number of diseases.

“We’re the idea factory for the next generation of molecules,” Mr. Freeman said. “Coming up with a new drug is not a cheap endeavor.”

The South Side-based company also has offices in Radnor, Pa.

Advertise with us

Series C funding, which Complexa received in the latest round, typically refers to the maturity of the company. The money is often used to grow the enterprise in a significant way with the help of hedge funds, investment banks and other large investors.

Food and Drug Administration approval will be needed for Complexa’s new product, which will require at least four clinical trials to prove safety and efficacy.

Complexa will use the new funding for Phase 2 clinical trials of its first drug candidate, called CXA-10, starting next year. The drug will be used in trials to treat focal segmental glomerulosclerosis, a rare kidney disease, and pulmonary arterial hypertension, which is high blood pressure in the lungs.

Up to 70 percent of the estimated 40,000 people in the U.S. with focal segmental glomerulosclerosis develop end-stage renal disease, according to Complexa. Patients have no approved therapeutic options.

Pulmonary arterial hypertension, or PAH,  which can cause difficulty breathing and heart failure, has a mean survival of five to seven years, according to Complexa. Some 25,000 people with the disease could benefit from treatment, but remedies are limited.

Advertise with us

Only 33 percent of Phase 2 drugs move on to Phase 3 trials, according to the FDA.

The funding round was the biggest in drug development in the Pittsburgh area in at least five years, said Gary Glausser, chief investment officer of  Innovation Works, the North Shore-based small business accelerator. The size of the investment round is a testament to the region’s pharmaceutical research heft.

“It’s cutting edge,” Mr. Glausser said. “It addresses large potential markets.”

In addition to Innovation Works, the Pittsburgh Life Sciences Greenhouse provided seed funding for Complexa in the early years.

Leading the latest Series C funding round were New Enterprise Associates, which in June closed the largest ever venture fund of $3.3 billion, and Pfizer Venture Investments LLC.

Advertise with us

Also participating were Edmond de Rothschild Investment Partners and HBM Healthcare Investments and existing investors including Jafco Co. Ltd, the former Japan Associated Finance Co. Ltd., which led the company’s Series B financing round in 2014.

Kris B. Mamula: kmamula@post-gazette.com or 412-263-1699